Ivowen Ltd1 Ivowen Limited Preparation and Submission of a Traditional Herbal Medicinal Product Application.

Slides:



Advertisements
Similar presentations
1 Harmonisation of requirements: where we are Erik Waterdrinker, IFAH-Europe 2nd Veterinary Workshop on E-submission 4 Dec 2009, EMEA, London.
Advertisements

BROMI Variations Training Meeting 8th May 2008 Case Study Session BROMI VARIATIONS.
Product information (II) – aspects relevant for ACTs Regine Lehnert Training workshop: Regulatory requirements for registration of Artemisinin based combined.
Submission Process. Overview Preparing for submission The submission process The review process.
IMP/Placebo Sourcing, Release, Storage and Reconciliation. Ms Caroline Whiriskey Research Pharmacist, HRB Clinical Research Facility Galway.
1 XXXXXXXXXXXXXXXXXXX, Malaysia, XXXXXX September, S.3.2 Impurities, Malaysia, 29 September 2011 Options for submitting API data to support.
1 Use and content of the RFP  Request for Proposals (RFP) is similar to bidding documents and include all information of the assignment, selection of.
Introduction to PPDs Regulatory requirements and rationale.
Federal agency for medicines and health products EXCIPIENTS IN THE LABLE AND PACKAGE LEAFLET OF HOMEOPATHIC MEDICINAL PRODUCTS Patricia Bodart – 23 October.
© 2005 Food Supplements Guidance Note Dr. Muireann Cullen Technical Executive
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Active Pharmaceutical Ingredient Master.
©2014 Factorytalk Co., Ltd. Proprietary and Confidential eCTD Specification 17 July 2014.
Slide 1 of 19D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Variations Maintenance of Prequalified.
Lynda Paleshnuik | January |1 | Assessment Workshop Copenhagen – January 2011 QIS/QOS: The new PQP quality templates.
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.
Structure of Dossier of Medicinal Product- Q part
Post approval changes- Variations Mercy Acquaye. Presentation Outline Introduction to Guidance Classification of changes Approval of changes Definitions.
The New EMC Directive 2004/108/EC and the DTI transposition Brian Jones and Peter Howick.
EFPIA EFPIA IT Proposals ppt Slide 1 EFPIA Proposals for IT Support to the European Regulatory Procedures Mr S. Hasler EFPIA PAT Regulation 2000.
Standards experts. Accreditation solutions. Andrea Spencer Coordinator, WTO/NAFTA Enquiry Point (Canada) TBT Special Meeting on Procedures for Information.
Training Session Product File Notes and Registration Reports, 23 October Registration Report: General aspects M. Trybou Federal Public Service of.
EU Food/Feed Safety Rules Industry Information Session June 16, 2005 Presented by AAFC.
ICH V1 An FDA Update Min Chen, M.S., RPh Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.
DMF Procedures and Communication between API, FP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
© Siemens AG 2014 Alle Rechte vorbehalten.siemens.com/lowvoltage New Legislative Framework (NLF) Sektor Infrastructure & Cities | Division Low and Medium.
1 Workshop on the Directive 96/61/EC concerning (IPPC) Integrated pollution prevention and control INFRA Public participation & access to environmental.
Regulating Herbal Medicines in Europe Heribert PITTNER Federal Ministry of Health and Women, Vienna, Austria 8th European Health Forum Gastein 7 October.
TECHNICAL REQUIREMENTS FOR MINOR APPLICATIONS E MOKANTLA 3 SEPTEMBER 2013.
DEPARTMENT OF HEALTH Medicines Regulatory Affairs
Meeting for EU Generic Manufacturers and EU MA holders for generic medicines, Copenhagen, 26 November 2009 Generics approved by stringent regulatory authorities:
An agency of the European Union Presented by: Emer Cooke and Truus Janse-de Hoog Update on Transparency Progress report from HMA/EMA TF on Transparency.
Project Guidelines for MBA Fourth Semester Students.
Paediatric Worksharing CMDh participation Work-sharing in Art 45 and 46 procedures Experiences in Art 29 procedures Presidency meeting 29 September 2011.
Theo Dekker -- CPH -- Nov |2 | Meeting of WHO PQP with European manufacturers and EU holders of marketing authorisations WHO Prequalification of.
WHO Workshop on Prequalification of Medicines Programme, Abu Dhabi, October, 2010 Regulatory principles reflected in practice of WHO PQP Milan Smid,
Federal agency for medicines and health products EC REGULATION 1901/2006 ON MEDICINAL PRODUCTS FOR PAEDIATRIC USE AND HOMEOPATHIC MEDICINAL PRODUCTS Marie-Anne.
1/33.  What is INDA ?  Types of INDAs  Objectives of INDAs  Format & Contents of an INDA  IND Safety reports  IND Annual Reports  IND Review Process.
HELM AG Module 3 Christa Clasen Ankara, 6./7. April 2006.
© AL IPA/EDQM/IDMA Symposium 2007, All rights reserved The Ph. Eur. policy on impurities Dr Andrea Lodi Deputy Head, Laboratory Department, EDQM, Council.
Lynda Paleshnuik | January |1 | Assessment Workshop Copenhagen – January 2011 The new PQP quality guideline.
CTD Dossier Preparation K. Srikantha Reddy Sr
1 Waste Discharge Authorization Application - British Columbia WG6 Application Process WG Document Review presented by Helga Harlander October x, 2008.
FDA ICH Public Meeting 5630 Fishers Lane, Rockville, MD May 8, :30 am -- 2:00 pm Implementation of the CTD Update-Issues-Next Steps Justina A. Molzon,
Scope of the Journal The International Journal of Sports Medicine (IJSM) provides a forum for the publication of papers dealing with basic or applied information.
JMAFF (Chair of Biologicals Quality Monitoring EWG)
Consumers, Health, Agriculture and Food Executive Agency 3rd Health Programme The Electronic Submission System (JA 2015) Georgios MARGETIDIS.
DMF Procedures and Communication between API, FFP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
Good Laboratory Practice - general information Pirkko Puranen Senior Inspector, Ph.D. Inspectorate.
Introduction to the CPR. Transition from CPD to CPR, key dates TAIEX Workshop INT MARKET CPR and CE marking, Baku, 23 and 24 February 2015.
DIA ERS SIAC IND CMC eCTD Submissions Part II – IND to NDA
1 Package on food improvement agents Food additives Food enzymes Flavourings Common procedure Developments since earlier consultation.
POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION
Dr Pascale POUKENS-RENWART Scientific Officer
Periodic Safety Update Reports (PSUR)
Information on Medicinal Products
Tender Evaluation and Award Process
REACH 2018 Find your co-registrants and prepare to register jointly.
CTD Content Management
REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.
International Open Procedure (1) – PRAG 4.3
Waiving Target Animal Batch Safety Testing for vaccines
GMP Inspection Process
EU SUBMISSION BY Haripriya & Revathy.
What the Editors want to see!
Recommendations to facilitate assessment of new application procedures
Prescription-only vs. over-the-counter medicines
EUnetHTA Assembly May 2018.
Quality guidelines on impurities
Presentation transcript:

Ivowen Ltd1 Ivowen Limited Preparation and Submission of a Traditional Herbal Medicinal Product Application

Ivowen Ltd2 Directive 2004/24/EC Traditional Herbal Medicinal Products Directive 2004/24/EC introduces a simplified registration procedure for traditional herbal medicinal products. This directive was transposed into Irish law – (SI No. 540 of 2007) on 23 July IMB established a Traditional Herbal Medicines Products Registration Scheme. An applicant can apply for a certificate of traditional- use registration for a THMP. This registration is called a traditional-use registration.

Ivowen Ltd3 National Regulation No medicinal product can be placed on the market without a prior MA (marketing authorisation) or certificate of traditional-use registration. The regulation however provides an exemption until 30 th April 2011 for THMP already on the market prior to the regulations coming into force. However IMB can request that applicants apply for a certificate of traditional-use registration before this date e.g. January 2010.

Ivowen Ltd4 First Steps Before Submission Familiarise yourself with EU legislation, Notice to Applicants, IMB guidance and HMPC guidance. Be sure that your product fulfils the criteria of a traditional herbal medicinal product. Prepare the documentation in the correct format and address all modules (where applicable). Obtain a company number and a product number (e.g. TR/xx/yy/zz) from The Receipts and Validation Section, IMB.

Ivowen Ltd5 Dossier Format Format of dossier is Common Technical Document (CTD). Guidance available specific for Herbals. The CTD is organised into five modules.

Ivowen Ltd6 CTD structure

Ivowen Ltd7 CTD structure Common Technical Document (CTD) Module 1: Administrative Information Module 2: CTD Summaries Module 3: Quality Module 4: Non-clinical Study Reports Module 5: Clinical Study Reports Each Module should be bound separately.

Ivowen Ltd8 Module 1 Module 1.1 – Comprehensive table of contents (Modules 1 – 5) Module 1.2 – Application form Module 1.3 – Product Information –1.3.1 – Summary of Product Characteristics, Labelling and Leaflet –1.3.2 – Mock-Up –1.3.3 – Specimen (NOT REQUIRED) –1.3.4 – Consultation with target patient groups –1.3.5 – SmPCs- already approved in Member States –1.3.6 – Braille

Ivowen Ltd9 Module 1 Module Information about the experts Quality Non-Clinical Clinical Module Specific requirements for different types of applications

Ivowen Ltd10 Module 1.2 Application Form The application form for a certificate of traditional-use registration in Ireland is the EU application Form. 2/b/update_ /applicformrevised_final.pdf 2/b/update_ /applicformrevised_final.pdf Summary of information required to complete form: –Product name + strength + form –Proposed Applicant/Marketing Authorisation Holder –Pharmacovigilance contact –Manufacturer of Substance + Product (including manufacturers authorisations)

Ivowen Ltd11 Module Product Information SmPC –As per Directive 2001/83/EC, Art. 11, as amended. –Includes the name, strength, form, quantity of active, posology, method of administration, indications, contraindications, excipients, shelf life and any special warnings and precautions for use (section 1- 4). Section 5 is not usually required.

Ivowen Ltd12 Module Product Information Labelling & Package Leaflet –Directive 2001/83/EC, Art 54 – 69, as amended. –The package leaflet should be drawn up in accordance with the Summary of Product Characteristics (SmPC). –Mock-ups (label/carton & Package leaflet) must be provided before final approval will be given.

Ivowen Ltd13 Module Consultation with Target Patient Groups Directive 2001/83/EC, Art 59-61, as amended. –Introduction of ‘user-testing’ to ensure that leaflets are easy to read and can be understood by the patient (patient-friendly language).

Ivowen Ltd14 Module Braille Directive 2001/83/EC Article 56 states that the name of the medicinal product should be expressed in Braille format on the packaging. You should include here the proposed braille text (in normal font) which will be printed on the outer carton along with the actual braille which is indicated with dots on the mock- ups. IMB request an additional braille statement to be included in this section.

Ivowen Ltd15 Module 1. 4 Information about the Experts Quality –Signature page along with CV from expert who prepared Module Non-Clinical –Signature page along with CV from expert who prepared Module Clinical –Signature page along with CV from expert who prepared Module 2.5.

Ivowen Ltd16 Module 1.5 Specific Requirements A brief summary/paragraph stating how this application meets the requirements for a traditional-use registration.

Ivowen Ltd17 Module 2 Module 2.1CTD Table of Contents Module 2.2Introduction Module 2.3Quality Overall Summary Module 2.4Nonclinical Overview Module 2.5Clinical Overview Module 2.6Nonclinical Summary Module 2.7Clinical Summary

Ivowen Ltd18 Module 2.3 Summary of Module 3. Cannot have additional data not already presented in Module 3. Sufficient information to provide assessor with complete overview of Module 3. Not more than 40 pages of text. Prescribed layout.

Ivowen Ltd19 Module 2.4 Summary of Module 4. Integrated and critical assessment of safety data of proposed product. Expert compiling this report must have appropriate experience and qualifications.

Ivowen Ltd20 Module 2.5 Summary of Module 5. The bibliographic or expert evidence of traditional-use (proof that the traditional herbal medicinal product or a corresponding product has been in medicinal use for at least 30 years (15 years must be in the EU) should be discussed.

Ivowen Ltd21 Module 3 Drug substance – 3.2.S Drug product – 3.2.P Regional information – 3.2.R Literature references – 3.3

Ivowen Ltd22 Module 3.2.S Drug substance – 3.2.S –3.2.S.1 General information –3.2.S.2 Manufacture –3.2.S.3 Characterization –3.2.S.4 Control of drug substance –3.2.S.5 Reference standards or materials –3.2.S.6 Container closure system –3.2.S.7 Stability

Ivowen Ltd23 Module 3.2.P Drug product – 3.2.P –3.2.P.1 Description and composition of the drug product –3.2.P.2 Pharmaceutical development –3.2.P.3 Manufacture –3.2.P.4 Control of excipients –3.2.P.5 Control of drug product –3.2.P.6 Reference standards or materials –3.2.P.7 Container closure system –3.2.P.8 Stability

Ivowen Ltd24 Module 3.2.A Facilities and equipment – biotech only. Adventitious agents safety evaluation. –TSE is most common entry in this section Novel excipients.

Ivowen Ltd25 Module 3.2.R Process validation scheme for the 3 consecutive production batches. Certificates of Suitability of Monographs of the European Pharmacopoeia. TSE certificates of suitability together with completed Table A on ‘Materials of animal origin’.

Ivowen Ltd26 Module 3.3 Literature references Any literature references used throughout the completion of Module 3 should be included in this section.

Ivowen Ltd27 Module 3-Summary In assembling the dossier for traditional-use registrations the applicant needs to take into account the scientific guidelines adopted by the CHMP/HCMP/Commission. Applicants need to be aware of all guidelines both general and specific and keep up to date with any revisions to guidance documents. European Pharmacopoeia standards are legally binding.

Ivowen Ltd28 Module 4 Safety Module 4.1 Introduction Module 4.2 Study Reports Module 4.3 Literature References –The bibliographic review should cover all safety aspects and should refer to a review of literature references and relevant published scientific literature. –More data may be requested in order to assess the safety of the product. –If the herbal substance (preparation/combination) is on the ‘list’, the data do not need to be provided.

Ivowen Ltd29 Module 5 Traditional-Use 5.1 Module 5 Table of Contents 5.2 Tabular Listing of All Clinical Studies 5.3. Clinical Study Reports 5.4 Literature References –Applicants should produce bibliographic or expert evidence documenting the traditional-use of the product for the proposed indication. – Evidence of use may be based on a similar product (same actives, strength, posology).

Ivowen Ltd30 Final Steps Ensure that each Module is bound separately, each section is clearly identified and each page is numbered. Ensure the correct number of copies (Electronic and/or Paper) is submitted. Ensure the correct fees are paid. Ensure the application is delivered to the correct address.

Ivowen Ltd31 After Submission An estimated 210 days to obtain a certificate of traditional-use registration. –Dependant on both the applicant and the agency.

Ivowen Ltd32 Ivowen Limited Any questions??